

11 DECEMBER, 2018

Camurus Capital Markets and R&D Day

IVA CONFERENCE CENTER, WALLENBERGSALEN
GREV TUREGATAN 16, STOCKHOLM, SWEDEN

AGENDA

Moderator: Charlotte Stjerngren, Cord Communications

12:45

Registration & coffee

13:00

Welcome and introduction by CEO Fredrik Tiberg

Buvidal® (CAM2038): A flexible-dose, weekly/monthly new treatment paradigm for opioid dependence

CEO, Head of R&D Fredrik Tiberg PhD

Ready for launch in Europe and Australia

CCO Richard Jameson

US commercialization of CAM2038 by Braeburn

CEO Mike Derkacz, Braeburn

Q&A

14:45

Coffee

15:00

Long acting somatostatin analogues for treatment of acromegaly and neuroendocrine tumours

Prof. Diego Ferone MD, PhD, University of Genoa, Italy

Trepostinil SC depot – a new treatment opportunity for pulmonary arterial hypertension and Scleroderma

James R. Seibold MD, Scleroderma Research Consultants, South Carolina

Next steps and concluding remarks

Q&A

16:30

Mingle & refreshments

ABOUT CAMURUS

Camurus is a Swedish research-based pharmaceutical company committed to developing innovative medicines for the treatment of severe and chronic conditions. New drug products are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com.

camurus®